Tabatha R. Simmons - Concepedia

Author

Tabatha R. Simmons

The Ohio State University ORCID

Also Known As

Dr. Tabatha Simmons, Simmons, T.R., T R Simmons, T. Simmons, T.R. Simmons, Tabatha R. Simmons, Tabatha Simmons

Publications

262

Citations

H-Index

Concepts

All Affiliations

The Ohio State University Nationwide Children's Hospital University of Utah Battelle

About

Tabatha R. Simmons is an author at The Ohio State University specializing in medicine, cell biology, and systems biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	113
2	Cell Biology	3	3	85
3	Language Studies	1	1	28
4	Natural Sciences	1	1	29
5	Biostatistics	1	1	28

Tabatha R. Simmons

Publications

234

Citations

H-Index

Page 1

	Year	Citations
Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce <i>DMD</i> Exon 2 Skipping Liubov V. Gushchina, E. Frair, N. Rohan, Human Gene Therapy	2021	39
A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2 Kevin M. Flanigan, Tatyana A. Vetter, Tabatha R. Simmons, Molecular Therapy — Methods & Clinical Development	2022	31
The first exon duplication mouse model of Duchenne muscular dystrophy: A tool for therapeutic development Adeline Vulin, Nicolas Wein, Tabatha R. Simmons, Neuromuscular Disorders Knockout MouseDevelopmental BiologyMendelian DisorderSkeletal MuscleDuchenne Muscular Dystrophy	2015	30
The ZZ Domain of Dystrophin in DMD: Making Sense of Missense Mutations Adeline Vulin, Nicolas Wein, Dana M. Strandjord, Human Mutation Missense MutationsMolecular RegulationMolecular BiologyZz DomainProtein Folding	2013	29
Increasing Genotype-Phenotype Model Determinism: Application to Bivariate Reading/Language Traits and Epistatic Interactions in Language-Impaired Families Tabatha R. Simmons, Judy F. Flax, Marco A. Azaro, Human Heredity GeneticsPsycholinguisticsGenomicsLanguage LearningGenome-wide Association Studies	2010	28
Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping Tabatha R. Simmons, Tatyana A. Vetter, Nianyuan Huang, Molecular Therapy — Methods & Clinical Development	2021	27
Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse Nicolas Wein, Tatyana A. Vetter, Adeline Vulin, Molecular Therapy — Methods & Clinical Development Duchenne Muscular DystrophyImmunologyAav9 Exon-skipping VectorDegenerative DiseaseGene Vector	2022	26
Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy Liubov V. Gushchina, Tatyana A. Vetter, E. Frair, Molecular Therapy — Nucleic Acids	2022	12
A genome-wide association analysis of loss of ambulation in dystrophinopathy patients suggests multiple candidate modifiers of disease severity Kevin M. Flanigan, Megan A. Waldrop, Paul T. Martin, European Journal of Human Genetics	2023	12

Page 1